

In timely response to the Office Action mailed May 8, 2002 within 1 month, pursuant to 37 CFR §1.7, extending the period of response to June 10, 2002 (As June 8, 2002 falls on a Saturday) Applicant respectfully requests consideration of the following remarks.

REMARKS

The instant Office Action (OA) newly requests election of species by the Applicant in addition to responding to the restriction requirement under 35 USC §121 submitted April 8, 2002. The Office has set forth in the Office Action, that "a reply to this requirement must include an identification of the species that is elected...and a listing of all claims readable thereon, including any claims subsequently added." (OA, p. 3). Applicant herein respectfully submits the requested species election.

Applicant, in response to the Restriction Requirement of January 10, 2002, elected Group II Claims without traverse:

II. Claims 25-37, drawn to polypeptides, classified in class 530, subclass 350.

In response to the instant Office Action, Applicant initially selects the polypeptide sequence of SEQ ID NO:10 (human zalpa11 Ligand polypeptide), and SEQ ID NO:4 (soluble IL2R γ receptor polypeptide) for the examination of claims 31 and 49, and 33 and 37, respectively. As such, claims 31, 49, 33, and 37 are subject to the species election; moreover, claims 32 and 52 are subject to the species election insofar as they depend from claim 31.


For clarification, claims 48-52 were newly added to the case pursuant to Preliminary Amendment January 10, 2002. Newly added claims 53-60 were withdrawn by the Office "[s]ince applicant has received an action on the Merits for the originally presented invention, this invention has been constructively elected by the original presentation for prosecution on the merits. Accordingly claims 53-60 have been withdrawn from consideration as being directed to a non-elected invention." (OA. p.2-3) Applicant acknowledges the Office's withdrawal of these claims without prejudice and will pursue them in a continuing or divisional application.

An Appendix with the instant claim set is provided for the Examiner's convenience, and shall not be construed as submission of a re-presented claim set under 37 CFR §1.121.

Early reconsideration and allowance of the pending claims is respectfully requested. If the Patent Examiner believes that a telephone interview would expedite prosecution of this patent application, please call the undersigned at (206) 442-6676.

Respectfully Submitted,

Scott Presnell, et al.

A handwritten signature in black ink, appearing to read "Jennifer K. Johnson", with a long horizontal flourish extending to the right.

Jennifer K. Johnson, J.D.

Registration No. 43,696

Enclosures:

Appendix (3 pages)

Postcard



1
COPY OF PAPERS
ORIGINALLY FILED

APPENDIX

Claim Set with Amended and Added Claims pursuant to the Preliminary Amendment of April 8, 2002; without withdrawn claims 53-60.

What is claimed is:

31. An isolated soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex; and

wherein the heterodimeric or multimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

32. An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor.

33. An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82).

35. An isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6.

36. An isolated heterodimeric or multimeric soluble receptor complex according to claim 35, further comprising a soluble Class I cytokine receptor polypeptide.

37. An isolated heterodimeric or multimeric soluble receptor complex according to claim 35, further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82).

48. An isolated heterodimeric receptor complex comprising two soluble receptor subunits, wherein the first soluble receptor subunit consists of a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and the second receptor subunit consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

49. An isolated heterodimeric receptor complex according to claim 48, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

50. An isolated heterodimeric receptor complex according to claim 48, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

51. An isolated heterodimeric or multimeric receptor soluble complex according to claim 35, wherein the soluble receptor complex further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

52. An isolated soluble receptor polypeptide according to claim 31, wherein the soluble receptor polypeptide further comprises an affinity tag, label, chemical moiety, toxin,

biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.